Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVTX-002 in poorly controlled non-eosinophilic asthma
NCT05288504Phase 2Completed
- Sponsor
- Avalo Therapeutics
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of quisovalimab in non-eosinophilic asthma (NEA), sponsored by Avalo Therapeutics. Started Feb 2022; status: completed.
02
Drugs
quisovalimab
03
Conditions
non-eosinophilic asthma (NEA)
Beyond the preview
Go deeper on NCT05288504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288504.